Isthmus Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Isthmus Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-226	Closed	-$46K	–	253
2021 Q2	$46K	Buy	+226	New	+$47.3K	0.01%	200
2018 Q4	–	Sell	-273	Closed	-$53K	–	274
2018 Q3	$53K	Hold	273	–	–	0.01%	177
2018 Q2	$46K	Hold	273	–	–	0.01%	182
2018 Q1	$44K	Hold	273	–	–	0.01%	183
2017 Q4	$41K	Hold	273	–	–	0.01%	185
2017 Q3	$42K	Hold	273	–	–	0.01%	183
2017 Q2	$35K	Hold	273	–	–	0.01%	198
2017 Q1	$30K	Hold	273	–	–	0.01%	205
2016 Q4	$20K	Hold	273	–	–	0.01%	223
2016 Q3	$22K	Hold	273	–	–	0.01%	212
2016 Q2	$23K	Hold	273	–	–	0.01%	198
2016 Q1	$22K	Sell	273 -273	-50%	-$24.7K	0.01%	199
2015 Q4	$62K	Buy	546 +273	+100%	+$33K	0.02%	170
2015 Q3	$28K	Hold	273	–	–	0.01%	209
2015 Q2	$34K	Hold	273	–	–	0.01%	196
2015 Q1	$32K	Hold	273	–	–	0.01%	196
2014 Q4	$32K	Buy	+273	New	+$30.7K	0.01%	204

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Isthmus Partners's VRTX Position: Q3 2021 in Review

Isthmus Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 226 shares — an estimated $46K sold.

Isthmus Partners first reported a position in VRTX in Q4 2014 and held it in 17 quarters. The position peaked at $62K in Q4 2015. 935 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Isthmus Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Isthmus Partners sold 226 Vertex Pharmaceuticals shares in Q3 2021, an estimated $46K.
Isthmus Partners first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 17 quarters.
Isthmus Partners's Vertex Pharmaceuticals position peaked at $62K in Q4 2015.
935 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Isthmus Partners's 13F filing for Q3 2021, filed 10 Nov 2021.